Table 5.
The comparison of PASI, BSA and DLQI scores between therapies with: MTX (therapy 1, n = 20), anti-TNFα (therapy 2, n = 20), anti-IL17a (therapy 3, n = 10) in patients with plaque psoriasis at two measurement points (week 0, week 12). * indicates a statistically significant difference (p < 0.05).
| Therapy 1 | Week 0 | Week 12 | Effect ( ↓ ) | |
| PASI | 12.11 ± 1.1 | 5.01 ± 0.8 | * 58% | |
| BSA | 9.28 ± 3.2 | 7.84 ± 1.3 | 15% | |
| DLQI | 22.86 ± 4.3 | 11.87 ± 1.1 | 48% | |
| Therapy 2 | PASI | 19.83 ± 1.4 | 4.49 ± 0.9 | * 77% |
| BSA | 42.23 ± 5.4 | 10.41 ± 2.4 | * 75% | |
| DLQI | 19.03 ± 1.2 | 6.16 ± 1.2 | * 67% | |
| Therapy 3 | PASI | 15.3 ± 2.1 | 8.29 ± 1.3 | 45% |
| BSA | 20.60 ± 3.8 | 6.20 ± 2.9 | * 69% | |
| DLQI | 18.40 ± 2.1 | 8.50 ± 1.1 | * 53% |